Brind.

Tempus and Biovica International mutually ended a potential partnership agreement while reviewing US commercial strategy.

2 reports, 1 independent Updated Sep 1
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Tempus and Biovica International mutually ended a potential partnership agreement while reviewing US commercial strategy.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Patent granted for immuno-oncology technology as Biovica terminated its US strategy agreement with Tempus.1 source
  2. Tempus and Biovica International terminated a potential partnership agreement.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped